Puma Biotechnology, Inc. (PBYI)
10.52
+0.32
(+3.14%)
USD |
NASDAQ |
Oct 15, 16:00
10.52
0.00 (0.00%)
After-Hours: 20:00
Puma Biotechnology Research and Development Expense (Quarterly) : 18.90M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 18.90M |
| March 31, 2026 | 19.80M |
| December 31, 2025 | 16.84M |
| September 30, 2025 | 15.91M |
| June 30, 2025 | 15.45M |
| March 31, 2025 | 13.86M |
| December 31, 2024 | 15.17M |
| September 30, 2024 | 12.55M |
| June 30, 2024 | 13.63M |
| March 31, 2024 | 13.59M |
| December 31, 2023 | 12.87M |
| September 30, 2023 | 11.45M |
| June 30, 2023 | 13.36M |
| March 31, 2023 | 12.71M |
| December 31, 2022 | 13.78M |
| September 30, 2022 | 11.25M |
| June 30, 2022 | 11.97M |
| March 31, 2022 | 15.24M |
| December 31, 2021 | 14.17M |
| September 30, 2021 | 18.84M |
| June 30, 2021 | 18.64M |
| March 31, 2021 | 20.23M |
| December 31, 2020 | 24.20M |
| September 30, 2020 | 23.34M |
| June 30, 2020 | 24.69M |
| Date | Value |
|---|---|
| March 31, 2020 | 25.46M |
| December 31, 2019 | 30.20M |
| September 30, 2019 | 30.03M |
| June 30, 2019 | 36.86M |
| March 31, 2019 | 35.73M |
| December 31, 2018 | 38.40M |
| September 30, 2018 | 36.36M |
| June 30, 2018 | 43.24M |
| March 31, 2018 | 46.92M |
| December 31, 2017 | 50.20M |
| September 30, 2017 | 49.50M |
| June 30, 2017 | 53.25M |
| March 31, 2017 | 54.80M |
| December 31, 2016 | 56.40M |
| September 30, 2016 | 51.98M |
| June 30, 2016 | 54.22M |
| March 31, 2016 | 60.21M |
| December 31, 2015 | 52.50M |
| September 30, 2015 | 51.92M |
| June 30, 2015 | 59.38M |
| March 31, 2015 | 44.73M |
| December 31, 2014 | 39.50M |
| September 30, 2014 | 32.09M |
| June 30, 2014 | 35.00M |
| March 31, 2014 | 16.29M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 7.341M |
| Arcutis Biotherapeutics, Inc. | 20.36M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Savara, Inc. | 21.95M |